Due to their inherent anti‐inflammatory properties (Romanelli et al., 2019), and observations that inflammation is observed in CF (Lin et al., 2018), we selected MSCs to produce engineered exosomes packaged with the CFTR activator CFZF‐VPR. This evidence concerns the gene CFTR and cystic fibrosis.